<SEC-DOCUMENT>0001104659-24-116420.txt : 20241112
<SEC-HEADER>0001104659-24-116420.hdr.sgml : 20241112
<ACCEPTANCE-DATETIME>20241112081018
ACCESSION NUMBER:		0001104659-24-116420
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		21
CONFORMED PERIOD OF REPORT:	20241112
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241112
DATE AS OF CHANGE:		20241112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Theriva Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		241443604

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Synthetic Biologics, Inc.
		DATE OF NAME CHANGE:	20120305

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2426982d2_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:syn="http://syntheticbiologics.com/20241112">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_syn_syntheticbiologics.com_20241112 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20241112_20241112 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0000894158 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000004" name="dei:EntityCentralIndexKey">0000894158</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="syn-20241112.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-11-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-12</xbrli:startDate>
        <xbrli:endDate>2024-11-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_909_edei--DocumentType_c20241112__20241112_zwSE4Lt83e48"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event
reported): <span id="xdx_904_edei--DocumentPeriodEndDate_c20241112__20241112_z27wAXAXHiv2"><ix:nonNumeric contextRef="AsOf2024-11-12" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">November 12, 2024</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityRegistrantName_c20241112__20241112_zZMnvUnW4nD4"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000011" name="dei:EntityRegistrantName">THERIVA BIOLOGICS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20241112__20241112_zucmIppFxDJd"><ix:nonNumeric contextRef="AsOf2024-11-12" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90A_edei--EntityFileNumber_c20241112__20241112_z5WTJSvKpHM6"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000013" name="dei:EntityFileNumber">001-12584</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 32%; padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_900_edei--EntityTaxIdentificationNumber_c20241112__20241112_zf9xaSzsi3E3"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000014" name="dei:EntityTaxIdentificationNumber">13-3808303</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center; padding-right: 0.8pt">(State or other jurisdiction of<br/>
incorporation)</td>
    <td style="padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: center"><span style="font-size: 10pt">(Commission File No.)</span></td>
    <td style="padding-right: 0.8pt; text-align: center">&#160;</td>
    <td style="text-align: center; padding-right: 0.8pt">(IRS Employer Identification<br/>
No.)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90A_edei--EntityAddressAddressLine1_c20241112__20241112_zWkJ7PrptCU1"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000015" name="dei:EntityAddressAddressLine1">9605 Medical Center Drive</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressAddressLine2_c20241112__20241112_zaYHEqg0Dp1e"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 270</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityAddressCityOrTown_c20241112__20241112_zNzqzZ0G6cV9"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000017" name="dei:EntityAddressCityOrTown">Rockville</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressStateOrProvince_c20241112__20241112_zccQkZj6Xhm1"><ix:nonNumeric contextRef="AsOf2024-11-12" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span> <span id="xdx_90D_edei--EntityAddressPostalZipCode_c20241112__20241112_z7gxizBnAKkg"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000019" name="dei:EntityAddressPostalZipCode">20850</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices and zip
code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_90A_edei--CityAreaCode_c20241112__20241112_zIjMA7fQu9gb"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000020" name="dei:CityAreaCode">301</ix:nonNumeric></span>) <span id="xdx_904_edei--LocalPhoneNumber_c20241112__20241112_z8d12dasO4Dg"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000021" name="dei:LocalPhoneNumber">417-4364</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font: 10pt Wingdings"><span id="xdx_90A_edei--WrittenCommunications_c20241112__20241112_zy1Kp5q3rwV1"><ix:nonNumeric contextRef="AsOf2024-11-12" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Wingdings"><span id="xdx_905_edei--SolicitingMaterial_c20241112__20241112_zM7hX3Ef39Ie"><ix:nonNumeric contextRef="AsOf2024-11-12" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act
(17 CFR 240.14a-12)</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Wingdings"><span id="xdx_908_edei--PreCommencementTenderOffer_c20241112__20241112_zpZqkRzZsQF1"><ix:nonNumeric contextRef="AsOf2024-11-12" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Wingdings"><span id="xdx_90B_edei--PreCommencementIssuerTenderOffer_c20241112__20241112_z8bIxd4d4Mr2"><ix:nonNumeric contextRef="AsOf2024-11-12" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; width: 33%; padding-left: 6.4pt; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 34%; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 33%; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Name of each exchange on<br/>
 which registered</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 6.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_901_edei--Security12bTitle_c20241112__20241112_zptsk37UBfTi"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000026" name="dei:Security12bTitle">Common stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_903_edei--TradingSymbol_c20241112__20241112_zzj1A0ODFKql"><ix:nonNumeric contextRef="AsOf2024-11-12" id="Fact000027" name="dei:TradingSymbol">TOVX</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_edei--SecurityExchangeName_c20241112__20241112_z1mDOlzXneLf"><ix:nonNumeric contextRef="AsOf2024-11-12" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">NYSE American</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company&#160;<span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_901_edei--EntityEmergingGrowthCompany_c20241112__20241112_zoXnxGFJ4bJ9"><ix:nonNumeric contextRef="AsOf2024-11-12" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by checkmark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 11%; padding-right: 0.8pt; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 2.02.</b></span></td>
    <td style="width: 89%; padding-right: 0.8pt; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results of Operations and Financial Condition.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 12, 2024, Theriva Biologics, Inc., a Nevada corporation
(the &#8220;Registrant&#8221;) issued a press release that included financial information for its quarter ended September 30, 2024. A
copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in this Item 2.02 and in the press
release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be &#8220;filed&#8221; for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2)
of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1
to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission
made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 11%; padding-right: 0.8pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01.</b></span></td>
    <td style="width: 89%; padding-right: 0.8pt; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%; padding-right: 0.8pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;</span></td>
    <td style="width: 96%; padding-right: 0.8pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 10%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br/>
Number</b></span></td>
    <td style="vertical-align: top; width: 1%; padding-right: 0.8pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 89%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="tm2426982d2_ex99-1.htm">99.1</a></span></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="tm2426982d2_ex99-1.htm">Press Release issued by Theriva Biologics, Inc., dated November 12, 2024</a></span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom; padding-right: 0.8pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the XBRL document)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>Dated: November 12, 2024</td>
    <td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THERIVA BIOLOGICS, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven A. Shallcross</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="width: 42%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven A. Shallcross</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjUEKwjAQRU/QOwxZS02j3XRpURGrSBFxG+0owTZTJrHqkbylsUUcBobh//e/ECOxpIWpkeE4KwvYY9PW2iOUeEFGe8bgyFfrDMIt8WqcZ219//7AnAKDgUljpU5B6K2dcVhlINNxko7VFOQkSyTsNiL66jnZi6nQeqNr0LaCHVPLBr3m15Cw10+y1Lz6qgOyM2QzSGI5yG9QMlGwpU4/iG8OiiIX0aifSCyZ7m1wzZ8e7ZeEeY1NqHMD/d/oAwQMSog= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2426982d2_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 99.1</B></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><IMG SRC="image_001.jpg" ALT="">&nbsp;</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Theriva&trade; Biologics Reports Third Quarter
2024 Operational Highlights and Financial Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Target patient enrollment of 92 evaluable patients
achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic pancreatic ductal adenocarcinoma </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Manufacturing funding awarded by the Spanish
Government&rsquo;s National Knowledge Transfer Program</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Data and Safety Monitoring Committee Review
of Phase 1b/2a SYN-004 in allogeneic hematopoietic cell transplant recipients recommends expansion to Cohort 3</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Orphan Medicinal Product Designation granted
by the European Commission to VCN-01 for the treatment of retinoblastoma</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Rare Pediatric Disease Designation granted by
the FDA for the treatment of retinoblastoma</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Placed Second in International Competition for
Merck KGaA&rsquo;s EMEA Advance Biotech Grant</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ROCKVILLE, Md., November 12, 2024 (GLOBE NEWSWIRE) &mdash; Theriva&trade;
Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases
in areas of high unmet need, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate
update.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We are very pleased to have completed enrollment in VIRAGE,
our Phase 2b trial in metastatic pancreatic ductal adenocarcinoma (PDAC) during the third quarter. Considering the tremendous need for
new therapies to treat pancreatic cancer, we have initiated discussions with regulatory agencies to explore the potential expansion of
the VIRAGE Phase 2b study into a registrational Phase 3 trial early next year, taking advantage of both Orphan Drug and Fast Track designations.
The novel mechanism of action of VCN-01 provides a unique opportunity to expand the treatment landscape in hard-to treat-cancers such
as PDAC and retinoblastoma and deliver new interventions that may significantly improve outcomes for patients, &ldquo; said Steven A.
Shallcross, Chief Executive Officer of Theriva Biologics. &ldquo;With funding from the Spanish Government and a small capital raise, we
are in a position to advance our proprietary suspension cell line towards larger scale manufacturing of VCN-01 for Phase 3 and commercial
use.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Recent Program Highlights and Anticipated Milestones:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>VCN-01:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in"><B>Pancreatic Ductal Adenocarcinoma (PDAC):</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 1%">&nbsp;</TD>
  <TD STYLE="text-align: center; width: 2%; vertical-align: top">&bull;</TD>
  <TD STYLE="width: 97%">Target of 92 evaluable patients (46 in each of the control and VCN-01 treatment arms) enrolled across 15 sites in Spain and the USA within 21 months in VIRAGE, the randomized, controlled, multicenter, open-label Phase 2b trial of VCN-01 in combination with standard-of-care chemotherapy (gemcitabine/nab-paclitaxel) as a first line therapy in newly diagnosed metastatic PDAC patients.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: top">&bull;</TD>
    <TD STYLE="width: 97%">Overall survival and progression free survival are the primary and key secondary endpoints respectively in the VIRAGE study. Both the
FDA and EMA previously granted fast track and orphan drug designations to VCN-01 for the treatment of PDAC.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: top">&bull;</TD>
    <TD STYLE="width: 97%">&nbsp;Initiated discussions with regulatory agencies to explore the potential expansion of the VIRAGE Phase 2b study into a Phase 3 registrational trial.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in"><B>Retinoblastoma:&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: top">&bull;</TD>
    <TD STYLE="width: 97%">The investigator sponsored Phase 1 trial evaluating the safety and activity of intravitreal VCN-01
in pediatric patients with refractory retinoblastoma has completed treatment and follow-up and the clinical study report is in
preparation. The results of the study were determined to be positive by the study Monitoring Committee and discussions with key
opinion leaders worldwide, as well as with regulatory agencies, are ongoing to refine our retinoblastoma clinical strategy.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: top">&bull;</TD>
    <TD STYLE="width: 97%">The European Commission adopted the European Medicines Agency (EMA) recommendation to grant orphan
medicinal product designation to VCN-01 for the treatment of retinoblastoma. FDA has previously granted orphan drug designation to
VCN-01 for the same indication.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: top">&bull;</TD>
    <TD STYLE="width: 97%">The U.S. FDA granted rare pediatric disease designation (RPDD) to VCN-01 to treat pediatric patients
with retinoblastoma. The FDA has previously granted orphan drug designation to VCN-01 in this indication.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: top">&bull;</TD>
    <TD STYLE="width: 93%">If a Biologics License Application for VCN-01 for the treatment of retinoblastoma is ultimately
approved by the FDA, Theriva may be eligible to receive a Priority Review Voucher that can be redeemed to receive a priority review
for any subsequent marketing application, or may be sold or transferred.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: top">&bull;</TD>
    <TD STYLE="width: 97%">Placed second of five finalists for Merck KGaA&rsquo;s EMEA Advance Biotech Grant which
celebrates standout emerging biotech companies. As a second-place finalist the company will receive financial support in
bioprocessing technologies and guidance on navigating the path to commercialization, including consultation with M Ventures.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I><IMG SRC="image_002.gif" ALT="">&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>SYN-004 (ribaxamase)</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: top">&bull;</TD>
    <TD STYLE="width: 97%">Successfully completed Cohort 2 of the Phase 1b/2a randomized, double-blinded, placebo-controlled
clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute
graft-versus-host-disease (aGVHD).</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: top">&bull;</TD>
    <TD STYLE="width: 97%">No AEs or SAEs were determined by the investigators to be related to study drug treatment. No
patient blood samples were positive for SYN-004 at any timepoint and the pharmacokinetics of co-administered piperacillin were as
expected for this patient population.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: top">&bull;</TD>
    <TD STYLE="width: 97%">The Data Safety and Monitoring Committee recommended continuation of the study and we are working
with the investigator to identify sources of funding to undertake Cohort 3.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Third Quarter Ended September 30, 2024 Financial Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses increased
to $2.3 million for the three months ended September 30, 2024, from $212,000 for the three months ended September 30, 2023. This increase
of 986% is primarily related to a $1.5 million decrease in contingent consideration during the three months ended September 30, 2023,
resulting in a reduction of prior period expenses and a $0.5 million increase in contingent consideration during the three months ended
September 30, 2024.&nbsp; Additionally, there was a decrease in investor relations expenses, Theriva S.L. expenses, and lower director
and officer insurance, offset by increased audit and registration fees. The charge related to stock-based compensation expense was $118,000
for the three months ended September 30, 2024, compared to $95,000 for the three months ended September 30, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses decreased to
$2.7 million for the three months ended September 30, 2024, from approximately $4.0 million for the three months ended September 30, 2023.
This decrease of 32% is primarily the result of lower clinical trial expenses related to our VIRAGE Phase 2 clinical trial of VCN-01 in
PDAC, lower expenses related to our Phase 1a clinical trial of SYN-020 which has completed, and lower expenses to our Phase 1b/2a clinical
trial of SYN-004 (ribaxamase) in allogeneic HCT recipients. We anticipate research and development expense to increase as we continue
our VIRAGE Phase 2 clinical trial of VCN-01 and plan for our Phase 3 clinical trial of VCN-01 in PDAC, advance our VCN-01 program in retinoblastoma,
expand GMP manufacturing activities for VCN-01, and continue supporting our other preclinical and discovery initiatives. The charge related
to stock-based compensation expense was $59,000 for the three months ended September 30, 2024, compared to $40,000 related to stock-based
compensation expense for the three months ended September 30, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended September 30, 2024,
we experienced a sustained decline in the quoted market price of our Common Stock and we deemed this to be a triggering event for impairment.
We performed an interim impairment analysis using the &ldquo;Income approach&rdquo; that requires significant judgments, including primarily
the estimation of future development costs, the probability of success in various phases of our development programs, potential post-launch
cash flows and a risk-adjusted weighted average cost of capital. We concluded that the in-process R&amp;D with a carrying value of $19.8
million was written down to its estimated fair value of $18.6 million and an impairment charge of $1.3 million was recorded, and goodwill
with a carrying value of $1.5 million was written down to its estimated fair value of zero and an impairment charge of $1.5 million was
recorded during the quarter. The decrease in the valuation was primarily driven by an increase in the discount rate which was impacted
by an increase in the company specific risk premium, and not by material changes to the clinical and administrative operations of the
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other income was $161,000 for the three months
ended September 30, 2024 compared to other income of $388,000 for the three months ended September 30, 2023. Other income for the three
months ended September 30, 2024 is primarily comprised of interest income of $158,000 and an exchange gain of $3,000. Other income for
the three months ended September 30, 2023 is primarily comprised of interest income of $382,000 and an exchange gain of $6,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cash and cash equivalents totaled $16.4 million as of September 30,
2024, compared to $23.2 million as of December 31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Theriva&trade; Biologics,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Theriva&trade; Biologics (NYSE American: TOVX), is a diversified clinical-stage
company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a
new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve
access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient&rsquo;s
immune system. The Company&rsquo;s lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively
within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer
treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal
(GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci)
and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients;
and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and
intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics&rsquo; website at&nbsp;<U>www.therivabio.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_004.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such
as &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; and similar expressions, and include statements
regarding t</I>he novel mechanism of action of VCN-01 providing a unique opportunity to expand the treatment landscape in hard-to treat-cancers
such as PDAC and retinoblastoma and deliver new interventions that may significantly improve outcomes for patients; being in a position
to advance the Company&rsquo;s proprietary suspension cell line towards larger scale manufacturing of VCN-01 for Phase 3 and commercial
use; <I>the potential expansion of the VIRAGE Phase 2b study into a Phase 3 registrational trial; the Company being eligible to receive
a Priority Review Voucher</I> for VCN-01 for the treatment of retinoblastoma; <I>and</I> identifying sources of funding for SYN-004 to
undertake Cohort 3<I>,. Important factors that could cause actual results to differ materially from current expectations include, among
others, the Company&rsquo;s and VCN&rsquo;s ability to reach clinical milestones when anticipated, including the ability generate clinical
data that establishes VCN-01 may lead to improved clinical outcomes for patients with PDAC and other solid cancers; the Company&rsquo;s
and VCN&rsquo;s product candidates demonstrating safety and effectiveness, as well as results that are consistent with prior results;
the ability to complete clinical trials on time and achieve the desired results and benefits; the ability to obtain regulatory approval
for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to the
Company&rsquo;s and VCN&rsquo;s ability to promote or commercialize their product candidates for the specific indications, acceptance
of product candidates in the marketplace and the successful development, marketing or sale of the Company&rsquo;s and VCN&rsquo;s products,
developments by competitors that render such products obsolete or non-competitive, the Company&rsquo;s and VCN&rsquo;s ability to maintain
license agreements, the continued maintenance and growth of the Company&rsquo;s and VCN&rsquo;s patent estate, the ability to continue
to remain well financed and other factors described in the Company&rsquo;s Annual Report on Form 10-K for the year ended December 31,
2023 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and current reports on Form 8-K. The information
in this release is provided only as of the date of this release, and Theriva Biologics undertakes no obligation to update any forward-looking
statements contained in this release on account of new information, future events, or otherwise, except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For further information, please contact:</B>&nbsp;<BR>
<B>Investor Relations:</B>&nbsp;<BR>
Chris Calabrese&nbsp;<BR>
LifeSci Advisors, LLC&nbsp;<BR>
ccalabrese@lifesciadvisors.com&nbsp;<BR>
917-680-5608</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_005.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Condensed Consolidated Balance Sheet</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(In thousands except share and par value amounts)</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30, 2024</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31, 2024</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Current Assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Cash and cash equivalents</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 13%; font: 10pt Times New Roman, Times, Serif; text-align: right">16,409</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 13%; font: 10pt Times New Roman, Times, Serif; text-align: right">23,177</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Tax credit receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,832</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,812</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 13.2pt">Prepaid expenses and other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,292</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,414</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 19.2pt">Total Current Assets</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">19,533</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">27,403</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Non-Current Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">314</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">422</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Restricted cash</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">103</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">102</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Right of use asset</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,428</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,759</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">In-process research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18,651</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19,755</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.1in; padding-left: 0.1in">Goodwill</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,700</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Deposits and other assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">79</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">78</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Total Assets</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">40,108</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">55,219</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; text-indent: -0.1in; padding-left: 0.1in">Liabilities and Stockholders&rsquo; Equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Current Liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Accounts payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">756</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">770</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Accrued expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,754</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,995</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Accrued employee benefits</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,291</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,517</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Deferred research and development tax credit-current portion</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">916</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">906</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Loans payable-current</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">65</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">63</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 13.2pt">Operating lease liability-current portion</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">541</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">487</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 19.2pt">Total Current Liabilities</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">7,323</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">6,738</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Non-current Liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Non-current contingent consideration</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,788</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,274</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Loan Payable - non-current</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">98</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">162</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Non-current deferred research and development tax credit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">229</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">906</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 13.2pt">Non-current operating lease liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,035</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,442</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Total Liabilities</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">15,473</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">15,522</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Commitments and Contingencies (Note 13)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Temporary Equity; 10,000,000 authorized</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Series C convertible preferred stock, $0.001 par value; 0 issued and outstanding at September 30, 2024, and 275,000&nbsp;issued and outstanding at December 31, 2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,006</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Series D convertible preferred stock, $0.001 par value; 0 issued and outstanding at September 30, 2024, and 100,000&nbsp;issued and outstanding at December 31, 2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">728</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Stockholders&rsquo; Equity:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Common stock, $0.001 par value; 14,000,000 shares authorized, 2,646,272 issued and 2,617,462 outstanding at September 30, 2024 and 715,028 issued and 686,219 outstanding at December 31, 2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Additional paid-in capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">355,333</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">346,536</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Treasury stock at cost, 28,809 shares at September 30, 2024 and at December 31, 2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(288</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(288</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Accumulated other comprehensive income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">112</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">32</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 13.2pt">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(330,525</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(309,318</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Total Stockholders&rsquo; Equity</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">24,635</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">36,963</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Total Liabilities and Stockholders&rsquo; Equity</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">40,108</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">55,219</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">All share numbers have been retrospectively adjusted
for the one to twenty-five reverse stock split effective August 26, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Condensed Consolidated Statements of Operations
and Comprehensive Loss</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(In thousands, except share and per share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Unaudited)</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">For the Three months ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">For the Nine months ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Operating Costs and Expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">General and administrative</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,302</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">212</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">5,702</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">5,099</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,734</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,006</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9,145</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,115</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">In-process research and development impairment</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,325</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,325</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 13.2pt">Goodwill impairment</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,526</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,594</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 19.2pt">Total Operating Costs and Expenses</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">7,887</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">4,218</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">21,766</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">15,214</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Loss from Operations</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(7,887</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(4,218</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(21,766</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(15,214</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Other Income/Expense:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 13.2pt">Foreign currency exchange gain</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 13.2pt">Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">158</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">382</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">559</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,127</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 19.2pt">Total Other Income</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">161</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">388</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">560</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,134</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net Loss</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(7,726</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(3,830</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(21,206</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(14,080</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Income tax benefit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">527</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,216</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Net Loss Attributable to Common Stockholders</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(7,726</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(3,303</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(21,206</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(12,864</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net Loss Per Share - Basic and Dilutive</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(6.81</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(4.85</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(24.47</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(20.38</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Weighted average number of shares outstanding during the period - Basic and Dilutive</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,134,391</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">681,708</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">866,529</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">631,387</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net Loss</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(7,726</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(3,303</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(21,206</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right">(12,864</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Gain (Loss) on foreign currency translation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">821</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(702</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">80</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(379</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Total comprehensive loss</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(6,905</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(4,005</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(21,126</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(13,243</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">All share numbers have been retrospectively adjusted
for the one to twenty-five reverse stock split effective August 26, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !' -4# 2(  A$! Q$!_\0
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M88UW.1QSCL/K70?%O_D1)O\ KO'_ #KD_A?X%TO6-+DU?58OM(,ICAA+$*,
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M;5+71=,GU"]<I;PC+$#)ZX 'ODUY-\(M7DTW7+[PY>90R$LBM_#*G##\0/\
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' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !' -4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBH;N\M
MK"V>YNYXX($&6DD8*!^)H2OL!-17D_BCXPQQ;[7P[%YC]#=RK\H_W5[_ %/Y
M5@:'\3O$.A7(CUN.:\MY?GQ.NR0 ]U..GMT],5W1P%9QYK?+J8.O!.Q[O17/
M6/BBV\2:/+/X=N;>6\"Y$-P2I0_[0Z_T]ZX./QIXF\/:Q+'K,;2JS9:&4;<#
MU0CM^8K*&&G.ZV:Z=2I58QMV/7:*Q]"\3:9X@AW6<X$H&6@?AU_#O]15F_US
M2M+E6._U&UM7<;E6:4*2/7FL7"2ERM:EJ2:O<OT5B_\ "7^&_P#H.Z?_ .!"
M_P"-'_"7^&_^@[I__@0O^-/V<_Y7]S#FCW-JBL[^W](_LXZA_:=I]C#[#/YH
MV;O3/3-6+'4+/4[;[18W45S#DKYD3AER.V14N,DKM#NBS1114C"BBB@ HHHH
M **KWM]:Z=:O=7MQ';P)]Z21L 4MI>6U_:I=6D\<\$@RLD;9!_&G9VN%^A/1
M112 **** "BBB@ HHHH *\4^-<LO]N:=#YC^3]FW;,_+NW,,X]<8KVNN#^(7
M@*?Q8T-[972QW5O&4$4@^5QDGKV/-=F"J1IUE*>QC6BY0:1B67AS0O!6DV&I
M36PO]0ND#I)<#Y(C@'A?QZ_RK<M(&\96C0ZWIT5S9')2Y/R-%_NG_/O4'C6T
MDCT'1H)1B2*+8PSG!"J#6MIEJ;GP!!9K.D,DJE$+-@$[R=OXXKIJU&L/[6UY
M-O\ 78\R\GBG!/2*O;37U/-M:^'>K^'Y_P"U?#-Y)>6\1W!K=OWT>/I][\/R
MKHO!^OWOC>W;2_$&B-=PQY!OU79L.._3#?[OY5MZ1Y?@NVN;C6KR./S0 D"M
MN9L9Y KEM<^(E_J):UTB(V4#'&5_UCY]QT_#\ZC#U:^*I+GA9]]K'3&2BN:6
ME^@WPI9)8?% VL3,8H)9XTW'G # 9KMO%G@&P\77L%U=W=S"T,?E@1;<$9)[
MCWKG? ?A+5K?6(M9OD\B,!B$D_UC[@1G';KWKT^IQ-9QJJ4):I6N;T87@U)=
M3P#X@^!;'PA:V,MI=7$QN'=6$NWC '3 'K6[X9^%.E:WX;L=2FO[R.6XCW,J
M;<#DCC(]JN?&[_D':1_UUD_DM=C\/_\ D0](_P"N/_LQKHGB*JPL9J6K9$:<
M?:M6T.1\:^'+?PO\+9=.M9I9H_M:2;I<9R3[?2H/ 7C+1/#/@:%-1NL3/<2%
M88UW.1QSCL/K70?%O_D1)O\ KO'_ #KD_A?X%TO6-+DU?58OM(,ICAA+$*,
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M;5+71=,GU"]<I;PC+$#)ZX 'ODUY-\(M7DTW7+[PY>90R$LBM_#*G##\0/\
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' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.gif
M1TE&.#EAU0!' /<  /______S/__F?__9O__,___ /_,___,S/_,F?_,9O_,
M,__, /^9__^9S/^9F?^99O^9,_^9 /]F__]FS/]FF?]F9O]F,_]F /\S__\S
MS/\SF?\S9O\S,_\S /\ __\ S/\ F?\ 9O\ ,_\  ,S__\S_S,S_F<S_9LS_
M,\S_ ,S,_\S,S,S,F<S,9LS,,\S, ,R9_\R9S,R9F<R99LR9,\R9 ,QF_\QF
MS,QFF<QF9LQF,\QF ,PS_\PSS,PSF<PS9LPS,\PS ,P _\P S,P F<P 9LP
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M,S.9 #-F_S-FS#-FF3-F9C-F,S-F #,S_S,SS#,SF3,S9C,S,S,S #, _S,
MS#, F3, 9C, ,S,   #__P#_S #_F0#_9@#_,P#_  #,_P#,S #,F0#,9@#,
M,P#,  "9_P"9S "9F0"99@"9,P"9  !F_P!FS !FF0!F9@!F,P!F   S_P S
MS  SF0 S9@ S,P S    _P  S   F0  9@  ,P
M
M
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M I>)1B092BFJ(^8B57G,&%H-DU[B)7IZ),T![G% ;$&(.CF)F$%.1)PQ4M)
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'M*!Q$A  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !' -4# 2(  A$! Q$!_\0
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M88UW.1QSCL/K70?%O_D1)O\ KO'_ #KD_A?X%TO6-+DU?58OM(,ICAA+$*,
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M;5+71=,GU"]<I;PC+$#)ZX 'ODUY-\(M7DTW7+[PY>90R$LBM_#*G##\0/\
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' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !' -4# 2(  A$! Q$!_\0
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M88UW.1QSCL/K70?%O_D1)O\ KO'_ #KD_A?X%TO6-+DU?58OM(,ICAA+$*,
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M;5+71=,GU"]<I;PC+$#)ZX 'ODUY-\(M7DTW7+[PY>90R$LBM_#*G##\0/\
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' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !' -4# 2(  A$! Q$!_\0
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M88UW.1QSCL/K70?%O_D1)O\ KO'_ #KD_A?X%TO6-+DU?58OM(,ICAA+$*,
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M;5+71=,GU"]<I;PC+$#)ZX 'ODUY-\(M7DTW7+[PY>90R$LBM_#*G##\0/\
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' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !' -4# 2(  A$! Q$!_\0
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M88UW.1QSCL/K70?%O_D1)O\ KO'_ #KD_A?X%TO6-+DU?58OM(,ICAA+$*,
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M;5+71=,GU"]<I;PC+$#)ZX 'ODUY-\(M7DTW7+[PY>90R$LBM_#*G##\0/\
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' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>syn-20241112.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaqOSbOdzZR+CYkxtmB9bVlK/ycqn11KkSX165tWEdoB -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:syn="http://syntheticbiologics.com/20241112" elementFormDefault="qualified" targetNamespace="http://syntheticbiologics.com/20241112">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://syntheticbiologics.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="syn-20241112_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="syn-20241112_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>syn-20241112_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>syn-20241112_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://syntheticbiologics.com/role/Cover" xlink:href="syn-20241112.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://syntheticbiologics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45214998737936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 12, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 12,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">THERIVA BIOLOGICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000894158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3808303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9605 Medical Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">417-4364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TOVX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M_&4\G%^0\61XA1!V"L+..81#R*=B$1DG(7\CW_A[%2.NY,%?YZ9)6QT$ZZ;
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @
M2$%L60=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " !(06Q9$]YYD>T    K @  $0
M@ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !(06Q9F5R<(Q &
M  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+
M 0(4 Q0    ( $A!;%D1>H2): 0  "D1   8              " @0P(  !X
M;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !(06Q9GZ ;\+$"
M  #B#   #0              @ &J#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( $A!;%F7BKL<P    !,"   +              "  88/  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( $A!;%FJQ"(6,P$  "("   /              "
M 6\0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !(06Q9)!Z;HJT   #X
M 0  &@              @ '/$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " !(06Q999!YDAD!  #/ P  $P              @ &T
L$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #^$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2426982d2_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://syntheticbiologics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>syn-20241112.xsd</File>
    <File>syn-20241112_lab.xml</File>
    <File>syn-20241112_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2426982d2_8k.htm">tm2426982d2_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>21
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2426982d2_8k.htm": {
   "nsprefix": "syn",
   "nsuri": "http://syntheticbiologics.com/20241112",
   "dts": {
    "schema": {
     "local": [
      "syn-20241112.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "syn-20241112_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "syn-20241112_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2426982d2_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://syntheticbiologics.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-11-12",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2426982d2_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-11-12",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2426982d2_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://syntheticbiologics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>22
<FILENAME>0001104659-24-116420-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-24-116420-xbrl.zip
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M]0K02CTC5E:!?E.5H+P6V^^7US==RT]RL]XD_UKAE,@M_P502P,$%     @
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M$].Q)5\F+5O,B[2"9R-/6,$OVHO[T5:6)L<5_MMD[RED"+PO,MGEP&0?496
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M7MF_-LD]?_GY"A6.C+11M)L6>*CB?JPR\U.?H:+;9'0\H*0'*X_W9H F?S.
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MV=[21'J91$'(X#6Y$<*@1_-[*XCD4S$RMA$J$>#<#YHN,#X NT8(O*,1([>
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M4$L! A0#%     @ 2$%L6;]G)J,O P  _@L  !               ( !
M '-Y;BTR,#(T,3$Q,BYX<V102P$"% ,4    " !(06Q9U*5,F_X*  " A@
M%               @ %= P  <WEN+3(P,C0Q,3$R7VQA8BYX;6Q02P$"% ,4
M    " !(06Q9&.W$'UX'  #H5P  %               @ &-#@  <WEN+3(P
M,C0Q,3$R7W!R92YX;6Q02P$"% ,4    " !(06Q9\1/ Q9T2  #\9P  $@
M            @ $=%@  =&TR-#(V.3@R9#)?.&LN:'1M4$L! A0#%     @
M2$%L62\8.&:#)@  =;L! !8              ( !ZB@  '1M,C0R-CDX,F0R
A7V5X.3DM,2YH=&U02P4&      4 !0!& 0  H4\

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>tm2426982d2_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="syn-20241112.xsd" xlink:type="simple"/>
    <context id="AsOf2024-11-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2024-11-12</startDate>
            <endDate>2024-11-12</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-11-12" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-11-12" id="Fact000004">0000894158</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-11-12" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-11-12" id="Fact000010">2024-11-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-11-12" id="Fact000011">THERIVA BIOLOGICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-11-12" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-11-12" id="Fact000013">001-12584</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-11-12" id="Fact000014">13-3808303</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-11-12" id="Fact000015">9605 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-11-12" id="Fact000016">Suite 270</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-11-12" id="Fact000017">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-11-12" id="Fact000018">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-11-12" id="Fact000019">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-11-12" id="Fact000020">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-11-12" id="Fact000021">417-4364</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-11-12" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-11-12" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-11-12" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-11-12" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-11-12" id="Fact000026">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-11-12" id="Fact000027">TOVX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-11-12" id="Fact000028">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-11-12" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
